[A26-53] Asciminib (CML, T315I mutation, previously treated) – Benefit assessment according to §35a Social Code Book V
Last updated 01.09.2026
Project no.:
A26-53
Commission:
Commission awarded on 26.05.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase with point mutation in the BCR::ABL protein at position 315 with threonine-isoleucine substitution who are resistant to, intolerant to or ineligible for ponatinib
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A26-53
| Project no. | Title | Status |
|---|---|---|
| A25-150 | Asciminib (CML, first- and second-line treatment) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A25-70 | Asciminib (chronic myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V | Commission completed |